Coronavirus and MS
Source Multiple Sclerosis International Federation: The coronavirus and MS – what you need to know
Coronavirus and MS Read More »
MS news
About MS
Masitinib Slows Disability Progression in PPMS and Non-active SPMS, Phase 2/3 Trial Reports
Source Multiple Sclerosis News Today: AB Science‘s masitinib significantly slowed disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) at a lower dose of 4.5 mg/kg a day, top-line results from a Phase 2b/3 clinical trial show.
MS Patients Switching from Tysabri to Other Therapies May Risk Disease Activity
Source Multiple Sclerosis News Today: Multiple sclerosis (MS) patients switching from Tysabri (natalizumab) to other disease-modifying therapies may have an increased risk of disease activity, though the risk is lower if the switch is limited to three months, a study found.
MS Patients Switching from Tysabri to Other Therapies May Risk Disease Activity Read More »
New guidance on MS Society grants
Source MS Society: Our Health and Wellbeing grants are there to help you pay for items that will have a significant positive impact on your life.
New guidance on MS Society grants Read More »
Online Fatigue- management course
Source MS Society: This online course will help you find ways to manage your MS fatigue and explain it to other people.
Online Fatigue- management course Read More »
Plegridy approved for relapsing remitting MS in England
Source MS Trust: NICE has published its final decision recommending that Plegridy can be prescribed by the NHS for relapsing-remitting MS.
Plegridy approved for relapsing remitting MS in England Read More »
It’s time to look at mountain escapes with a fresh perspective.
Source Winter Sports Travel: Making Travel Accessible. Winter sports are becoming more accessible than ever before. But finding the right place or activity when you’re living with a challenging condition can be tough. Try this tool to find sports and resorts in Europe that are tailored to your needs. Click here.
It’s time to look at mountain escapes with a fresh perspective. Read More »
Siponimod licensed for secondary progressive MS
Source MS Society: This week the European Medicines Agency (EMA) granted a license for siponimod (brand name Mayzent) to treat adults with secondary progressive MS with active disease.
Siponimod licensed for secondary progressive MS Read More »
New Study Asks: When Does MS Begin?
Source National Multiple Sclerosis Society: Researchers from the Harvard T.H. Chan School of Public Health in Boston and collaborators report on a study that examined blood (serum) samples from 60 military personnel who went on to develop multiple sclerosis years later. Compared to samples from a control group, those who eventually developed MS showed higher than
New Study Asks: When Does MS Begin? Read More »
MS Progression Affected by Degree of Relapse Recovery and Timing of DMT Use, Study Says
Source Multiple Sclerosis News Today: Recovering well after a first relapse and starting a disease-modifying therapy (DMT) immediately afterwards considerably increases the likelihood of slowing progression in multiple sclerosis (MS), a study suggests. Its findings support relapse recovery as a critical factor for DMT initiation, and one that should be assessed routinely in MS clinical trials, researchers said. The
MS Progression Affected by Degree of Relapse Recovery and Timing of DMT Use, Study Says Read More »